Actuate Therapeutics sets annual meeting for May 22

Actuate Therapeutics , Inc., a biopharmaceutical company with a market capitalization of $172 million, announced today that it will hold its first Annual Meeting of Stockholders virtually on May 22, 2025. The meeting comes just months after the company’s next earnings report, scheduled for February 26, 2025. In preparation for the Annual Meeting, the company has declared March 25, 2025, as the record date, which will determine the stockholders eligible to receive notice and vote at the event.

The company’s Board of Directors will provide further information on the topics to be voted on at the Annual Meeting. According to InvestingPro data, Actuate Therapeutics is not currently profitable, with negative earnings per share of -$7.37 over the last twelve months. Details will be included in the proxy statement, which will be filed with the Securities and Exchange Commission and made available to stockholders prior to the meeting.

Stockholders interested in submitting proposals for consideration at the Annual Meeting have until the close of business on February 21, 2025, to present their proposals. Want deeper insights into Actuate Therapeutics’ financial health? InvestingPro subscribers have access to over 30 additional financial metrics and analysis tools. These must be in line with Rule 14a-8 of the Securities Exchange Act and comply with all relevant laws and regulations to be included in the proxy materials.

Additionally, for stockholders aiming to nominate directors or present other proposals not covered by Rule 14a-8, the company’s Amended and Restated Bylaws outline an advance notice procedure. To meet these requirements, stockholders must submit the necessary information and adhere to the Bylaws’ stipulations by the February 21, 2025 deadline.

The announcement of the Annual Meeting and associated deadlines is based on a press release statement. Actuate Therapeutics, Inc. operates under the (NASDAQ:ACTU) ticker and is classified under the pharmaceutical preparations industry, with its headquarters located in Fort Worth, Texas. Despite current market challenges, the company maintains a strong financial health score of 3.59 out of 5 according to InvestingPro analysis.

In other recent news, Actuate Therapeutics, Inc. has made significant strides in its drug development efforts. The company’s drug, elraglusib, earned Orphan Medicinal Product Designation from the European Medicines Agency for the treatment of pancreatic ductal adenocarcinoma. This regulatory milestone could expedite elraglusib’s development and market exclusivity in the European Union.

In addition, Actuate reported substantial findings from its Phase 2 trial of elraglusib in combination with chemotherapy for metastatic pancreatic cancer. The trial showed a significant improvement in survival rates and a reduction in the risk of death. The company plans to discuss the topline data and the prospects of a Phase 3 registration trial with the FDA in the first half of 2025.

Furthermore, the U.S. Food and Drug Administration granted rare pediatric disease designation to elraglusib for the treatment of Ewing sarcoma. This is a critical milestone for elraglusib, which is currently being evaluated in a Phase 1/2 trial for safety and efficacy in pediatric patients with relapsed or refractory malignancies, including Ewing sarcoma. These are recent developments in the company’s ongoing mission to develop therapies for high-impact, difficult-to-treat cancers.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.